Peptide Reconstitution and Concentration: The Lab Math, Step by Step

Reconstitution is the point where a documented, stable powder becomes a solution with a concentration you are responsible for knowing. The arithmetic is simple, but it is also where most avoidable error enters a research record: a volume estimated rather than measured, a vial label read as though it were the peptide mass, or a concentration written down without the units that make it meaningful. This guide walks through the calculation itself, how to choose a reconstitution volume, and what belongs in the record afterwards.

Quick answer

How do you calculate the concentration of a reconstituted peptide? Divide the mass of peptide in the vial by the volume of diluent added. A 10 mg vial reconstituted with 2 mL gives 5 mg/mL. The formula is concentration = mass ÷ volume, and 1 mg/mL is the same as 1 µg/µL. Two things make the result meaningful: measuring the volume rather than estimating it, and knowing that the label mass describes the peptide, not the total powder weight.

The three numbers that define a stock solution

Every reconstituted vial is described by three quantities, and any two of them determine the third.

Quantity	Symbol	Typical units	Where it comes from
Mass of peptide	m	mg	The vial label and the lot certificate
Volume of diluent	V	mL	What you measure and add
Concentration	C	mg/mL	Calculated: C = m ÷ V

Rearranged, the same relationship answers the other two questions a bench worker asks. To reach a target concentration, V = m ÷ C. To find how much peptide sits in a given volume of your stock, m = C × V.

A unit conversion worth memorising

Milligrams per millilitre and micrograms per microlitre are numerically identical. One mg/mL is one µg/µL, because both the mass and the volume are divided by a thousand. A 5 mg/mL stock is therefore also a 5 µg/µL stock, which is the more convenient way to think about it when you are working with microlitre volumes on a bench.

Expression	Equivalent
1 mg/mL	1 µg/µL
1 mg/mL	1000 µg/mL
1 mg	1000 µg
1 mL	1000 µL

Reference table: concentration by vial size and volume

The table below gives the resulting concentration in mg/mL for the vial sizes commonly supplied as lyophilized research material. Read down the column for the volume you intend to add.

Vial mass	+ 1 mL	+ 2 mL	+ 3 mL	+ 5 mL	+ 10 mL
5 mg	5 mg/mL	2.5 mg/mL	1.67 mg/mL	1 mg/mL	0.5 mg/mL
10 mg	10 mg/mL	5 mg/mL	3.33 mg/mL	2 mg/mL	1 mg/mL
20 mg	20 mg/mL	10 mg/mL	6.67 mg/mL	4 mg/mL	2 mg/mL
50 mg	50 mg/mL	25 mg/mL	16.7 mg/mL	10 mg/mL	5 mg/mL
80 mg	80 mg/mL	40 mg/mL	26.7 mg/mL	16 mg/mL	8 mg/mL
100 mg	100 mg/mL	50 mg/mL	33.3 mg/mL	20 mg/mL	10 mg/mL

The higher concentrations in the upper-left of this table are theoretical rather than automatic. Whether a peptide will actually dissolve at 80 or 100 mg/mL depends on its sequence, and a compound that resists going into solution needs a different approach rather than more force; see peptide solubility and choosing a diluent.

Why the label mass is not always the peptide mass

A vial labelled 10 mg contains 10 mg of the material as weighed out, and that material is not pure peptide. Counter-ions from purification, residual water and residual solvent all contribute weight. Net peptide content is the share of the powder that is actually peptide, and it is commonly in the 70 to 90 percent range for a trifluoroacetate salt.

For most comparative work at the bench this distinction can be handled by keeping conditions consistent across a study. For quantitative work where the true molar concentration matters, the correction is straightforward: multiply the label mass by the net peptide content before dividing by volume. A 10 mg vial at 80 percent net peptide content reconstituted in 2 mL gives 4 mg/mL of peptide, not 5 mg/mL. The full explanation is in net peptide content vs purity, and the figure itself comes from the lot certificate, not from an assumption.

Choosing a reconstitution volume

There is no single correct volume. The choice is a trade-off between four practical constraints.

• Pipetting accuracy. Very concentrated stocks require very small transfer volumes, and small volumes carry proportionally larger pipetting error. Diluting further usually costs less precision than trying to move 2 µL reproducibly.
• Solubility. The stock has to actually dissolve. Hydrophobic sequences may need a lower concentration or a different initial solvent.
• Aliquot planning. A volume that divides cleanly into the number of aliquots you need avoids leftover fractions and repeated handling of the parent vial.
• Vial headroom. The diluent has to fit. A 2 mL vial cannot take 5 mL, and overfilling risks contact between the solution and the closure.

A common default is to pick a volume that puts the stock in a range where routine transfers land between 10 and 100 µL, then work from there.

Adding the diluent

Technique matters less than arithmetic but it is not irrelevant. Lyophilized peptides are physically delicate and mechanically agitating a solution promotes aggregation.

1. Let the vial reach room temperature before opening it. Cold glass condenses atmospheric moisture, and water is what the freeze-drying removed in the first place.
2. Measure the diluent rather than estimating from graduations on a syringe barrel.
3. Direct the stream down the inner wall of the vial rather than onto the powder cake.
4. Let it stand, then swirl or roll gently. Do not shake, and do not vortex a peptide solution as a first resort.
5. Inspect against light before use. A clear solution with no visible particulate is the expected result.

The diluent itself is part of the experiment. Bacteriostatic water contains 0.9 percent benzyl alcohol as a preservative, and sterile water does not; the two are not interchangeable in a record. Bacteriostatic water vs sterile water covers the difference, and why diluent choice matters for reproducibility explains why it belongs in your documented conditions. Revoryn Labs supplies bacteriostatic water (10 ml) as a laboratory reagent for this purpose.

What changes the moment a peptide is in solution

A dry, sealed lyophilized powder is the stable form. Once water is added, the chemistry that freeze-drying suppressed becomes available again: hydrolysis, deamidation of asparagine and glutamine, oxidation of methionine and cysteine, and physical aggregation. Manning and colleagues review these pathways in detail for peptide and protein pharmaceuticals, and the practical consequence is consistent across sequences. Solutions have a working life measured in days to weeks under refrigeration, while the sealed powder is measured in months to years.

That asymmetry is the argument for aliquoting. Dividing a stock into single-use portions at the time of reconstitution means the bulk of the material experiences one freeze-thaw cycle rather than ten, and the parent solution is not repeatedly opened, warmed and re-chilled. See peptide degradation explained and what degrades a peptide after reconstitution.

A worked example

A researcher receives a 50 mg vial of GHK-Cu and wants a stock that delivers convenient microlitre transfers, with ten single-use aliquots.

• Target: 10 aliquots, so a volume that divides by ten. Choose 5 mL.
• Concentration: 50 mg ÷ 5 mL = 10 mg/mL, which is 10 µg/µL.
• Aliquot size: 5 mL ÷ 10 = 0.5 mL per tube, each containing 5 mg.
• Correction: if the certificate reports 82 percent net peptide content, the peptide concentration is 50 × 0.82 ÷ 5 = 8.2 mg/mL.

Both numbers go in the record. The nominal 10 mg/mL describes what was prepared; the 8.2 mg/mL describes what is in it.

What to write down

A reconstitution entry that another person could reproduce contains the compound and lot number, the label mass, the diluent and its own lot, the measured volume, the calculated concentration with units, the net peptide content used for any correction, the date and time, and the storage condition the aliquots went into. The lot number is what ties the whole entry back to a certificate; if you are unsure what the certificate is telling you, how to read a certificate of analysis works through it field by field. Revoryn Labs publishes available batch documentation in its public COA ledger, matched to the lot printed on the vial.

Revoryn Labs does not publish usage instructions, protocols or administration guidance of any kind for any product. The calculations above describe laboratory concentration, and nothing more.

Key takeaways

• Concentration is mass divided by volume: a 10 mg vial in 2 mL is 5 mg/mL.
• 1 mg/mL and 1 µg/µL are the same number, which makes microlitre work easier to reason about.
• The label mass includes counter-ions and water; net peptide content from the certificate corrects it.
• Choose a volume that keeps routine transfers large enough to pipette accurately and divides cleanly into aliquots.
• Stability drops sharply once a peptide is in solution, which is why aliquoting at reconstitution is worth the extra tubes.

Frequently asked questions

How do I calculate mg/mL for a peptide vial?

Divide the mass of peptide in the vial by the volume of diluent you add. A 20 mg vial reconstituted with 4 mL gives 5 mg/mL.

How much diluent should I add to a peptide vial?

Enough to reach a concentration you can pipette accurately and that divides into the aliquots you need, while staying within the vial capacity and the peptide solubility. There is no universal volume; it is chosen per experiment and recorded.

Is 1 mg/mL the same as 1 µg/µL?

Yes. Dividing both the mass and the volume by one thousand leaves the ratio unchanged, so the two expressions are numerically identical.

Does a 10 mg vial contain 10 mg of peptide?

Not exactly. It contains 10 mg of lyophilized material, part of which is counter-ion, residual water and residual solvent. The net peptide content on the lot certificate gives the peptide share.

How long does a reconstituted peptide last?

Far less time than the sealed powder. Solutions are generally handled on a scale of days to weeks under refrigeration, depending on sequence and conditions, whereas dry lyophilized material is stable for far longer. Aliquoting limits freeze-thaw cycles.

Sources

• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
• Merck / Sigma-Aldrich. Synthetic Peptide Handling & Storage Protocol. sigmaaldrich.com
• Bachem. Peptide solubility, technical note. bachem.com

For laboratory and in-vitro research use only. Not for human or veterinary use.